Related Experiment Videos
[Therapeutic efficacy and prognostic factors in diffuse astrocytomas]
Takao Watanabe1, Chiaki Komine, Takakazu Yokoyama
1Department of Neurological Surgery, Nihon University School of Medicine, Japan.
No Shinkei Geka. Neurological Surgery
|July 30, 2003
Summary
Radical surgery and interferon-beta therapy significantly improved survival for diffuse astrocytoma patients. MGMT gene promoter hypermethylation predicted shorter progression-free survival, suggesting potential for targeted chemotherapy.
Area of Science:
- Neuro-oncology
- Cancer genetics
- Clinical trial analysis
Context:
- Diffuse astrocytomas are slow-growing brain tumors with variable treatment outcomes.
- Optimal therapeutic strategies for WHO grade II astrocytomas remain debated.
- Retrospective analysis of 64 patient cases provides insights into prognostic factors.
Purpose:
- To evaluate the impact of different therapeutic interventions on progression-free survival (PFS) and overall survival (OS) in diffuse astrocytomas.
- To identify independent predictors of survival in patients with WHO grade II astrocytomas.
- To explore the role of O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation in treatment response.
Summary:
- Gross total resection and interferon-beta therapy were associated with significantly longer PFS and OS.
- Immediate postoperative radiation therapy did not demonstrate a significant benefit for PFS or OS.
- MGMT gene promoter hypermethylation was an independent predictor of shorter PFS.
Impact:
- Radical surgery combined with interferon-beta therapy may represent an optimal treatment approach for improved long-term survival.
- MGMT methylation status could guide therapeutic decisions, potentially identifying patients who may benefit from early chemotherapy with alkylating agents.
- Findings contribute to personalized treatment strategies for diffuse astrocytomas based on molecular markers.